A Pilot Study Using Carboplatin, Vincristine and Temozolomide for Children < 10 Years with Progressive/Symptomatic Low-Grade Gliomas (ACNS022)

IRB# 2006-070  
Principal Investigator:  Joseph Torkildson, MD

Synopsis:
Carboplatin and vincristine are active agents in the management of progressive and/or symptomatic low-grade gliomas. However the use of this combination does not prevent progression in a substantial number of patients. In addition carboplatin is associated with significant allergic reactions requiring cessation of therapy in a relatively large number of patients. The purpose of this study is to identify active agents which along with the known active agents can provide an alternative regimen to the management of these patients. Temozolomide is one such agent which in a phase II study induced stable disease, with 41% percent of patients with progressive disease at study entry completing 12 courses of temozolomide with stable disease. This is a COG groupwide pilot study to determine the feasibility and toxicity of an induction and maintenance regimen with cycles consisting of carboplatin, vincristine with temozolomide. Carboplatin and vincristine followed by temozolomide will be administered both in induction and maintenance. Induction will consist of one cycle of carboplatin/vincristine followed by temozolomide for 10 weeks duration. Induction will be followed by maintenance with six 10-week cycles of carboplatin/vincristine with temozolomide.